HGHaniyeh Golafrouz

Haniyeh Golafrouz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haniyeh Golafrouz has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Curcumin/Turmeric Supplementation on Glycemic Control in Adults With Prediabetes and Type 2 Diabetes: A Systematic Review and Dose–Response Meta‐Analysis

    by Hossein Bahari, Mostafa Shahraki Jazinaki, Zahra Asadi, Haniyeh Golafrouz

    Curcumin and turmeric have demonstrated potential hypoglycemic properties in preclinical studies, but findings from human randomized controlled trials (RCTs) in prediabetes and type 2 diabetes (T2D) are inconsistent. PubMed, Scopus, and Web of Science ISI databases were comprehensively searched until August 2025 (25/08/2025) to find eligible RCTs. Overall effect sizes were estimated based on the random‐effect models and presented as weighted mean differences (WMD) with 95% confidence intervals (95% CI). All analyses were performed using version 17.0 (Stata Corp., College Station, TX, USA). Thirty‐four eligible RCTs (39 treatment arms) were included in this review. Curcumin/turmeric supplementation significantly reduced fasting blood glucose (FBG) (WMD = −10.15 mg/dL; 95% CI: −12.59, −7.72), hemoglobin A1c (HbA1c) (WMD = −0.32%; 95% CI: −0.43, −0.21), fasting insulin (WMD = −0.69 μU/ml; 95% CI: −1.27, −0.12), homeostatic model assessment of insulin resistance (HOMA‐IR) (WMD = −0.46; 95% CI: −0.60, −0.32), and oral glucose tolerance test (OGTT) (WMD = −11.53 mg/dL; 95% CI: −22.68, −0.44) compared to control groups. However, no significant alteration in homeostatic model assessment of β ‐cell function (HOMA‐B) levels was detected, followed by Curcumin or turmeric supplementation in comparison to the control groups. Subgroup analyses indicated that efficacy was modified by health status (T2D vs. prediabetes), dosage (≥ 1 g/day more effective), and formulation. This meta‐analysis revealed that curcumin/turmeric supplementation may improve glycemic control in individuals with prediabetes or T2D. Despite positive findings, significant heterogeneity across studies necessitates caution. Furthermore, future high‐quality RCTs are required to reach a firm conclusion.


  • Open Access

    Antihypertensive Effects of Curcumin/Turmeric Supplementation in Prediabetes and Diabetes: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

    by Hossein Bahari, Maryam Sharifi, Zahra Nejad Shahrokh Abadi, Mostafa Shahraki Jazinaki, Haniyeh Golafrouz, Zahra Asadi

    Introduction: Hypertension is a major cardiovascular risk factor in individuals with prediabetes and type 2 diabetes (T2D). Curcumin, with its anti‐inflammatory and antioxidant properties, has emerged as a potential adjunct therapy, but its effect on blood pressure in this population remains unclear. Aims: This meta‐analysis aimed to evaluate the effects of curcumin or turmeric supplementation on systolic (SBP) and diastolic (DBP) blood pressure in adults with prediabetes or T2D. Methods: A systematic search of PubMed, Scopus, and Web of Science was conducted until August 2025. Randomised controlled trials (RCTs) investigating curcumin/turmeric supplementation on blood pressure in adults with prediabetes or T2D were included. A meta‐analysis was performed using a random‐effects model. Results: Fifteen RCTs comprising 16 treatment arms ( n = 855 participants) were included. Pooled results indicated that curcumin/turmeric supplementation significantly reduced SBP (WMD: −2.69 mmHg; 95% CI: −3.84 to −1.55; p < 0.001; I 2 = 30.1%) compared to control groups. A more substantial reduction in SBP (−3.41 mmHg) was observed in the subgroup of participants with baseline hypertension (SBP ≥ 130 mmHg). However, no significant effect was found on DBP (WMD: −1.20 mmHg; 95% CI: −2.84 to 0.44; p = 0.15; I 2 = 84.3%). Subgroup analyses showed significant reductions in SBP in individuals with T2D or prediabetes, in those who were overweight, and with interventions using nano‐curcumin, turmeric, or curcumin with piperine at doses > 1 g/day. In addition, subgroup analysis showed that curcumin/turmeric supplementation led to a significant reduction in DBP in individuals with T2D. Conclusions: Curcumin/turmeric supplementation demonstrates a modest, yet significant reduction in SBP in individuals with prediabetes and diabetes, with a more pronounced effect in those with baseline hypertension. Further high‐quality RCTs are needed to confirm these findings and establish optimal dosing.